Research
Hormonal
58.3% of patients achieved a weight reduction of 5% or more at six months.
A significant portion of obese IBD patients may benefit from GLP-1 agonist therapy for weight loss.
StrongSupportsmedium confidence
a 5 % or more weight reduction was achieved in 58.3 % (7/12) of patients at six months.
Why this rating
Based on the retrospective analysis of a specific patient cohort.
Source
Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease
Clara Ramos Belinchón et al. · Revista Española de Enfermedades Digestivas · 2024
cohort · n=16Cited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →